VivoSeq
Other

Bloodstream Infection

0

Pipeline Programs↗

7

Active Trials↗

3

Companies Involved↗

Bloodstream Infection is an early-stage landscape with 0 programs across 3 companies. The most active players are BioWest Therapeutics Inc, Vicuron Pharmaceuticals, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BioWest Therapeutics Inc

0 programs

PreclinicalV

Vicuron Pharmaceuticals

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed9 · 39%
Recruiting7 · 30%
Terminated2 · 9%
Unknown status2 · 9%
Withdrawn2 · 9%
No longer available1 · 4%

Clinical Trials

Trial Activity

23 trials

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Recruiting·JJohns Hopkins University·N/A·NCT06080698·1,030 enrolled
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
Recruiting·CCorMedix·Phase 4·NCT06714864·36 enrolled
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Recruiting·CCorMedix·Phase 3·NCT06822426·200 enrolled
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
Recruiting·RRambam Health Care Campus·Phase 4·NCT03671967·1,084 enrolled
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05117398·406 enrolled
BACTERIUM: Study for a Machine-learning-based Model to Predict Bloodstream Infections
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT05876598·5,000 enrolled
The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome: a Randomized Clinical Trial Within an Adaptive Platform Trial for Patients With Bloodstream Infections
Recruiting·IIstituto Clinico Humanitas·Preclinical·NCT07491419·400 enrolled
Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01321879·40 enrolled
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
Completed·CCorMedix·Phase 3·NCT02651428·806 enrolled
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
Completed·BBioWest Therapeutics Inc·Phase 3·NCT00027248·1,400 enrolled
Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections
Completed·—·N/A·NCT05376566·212 enrolled
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Completed·—·Phase 4·NCT02095951·30 enrolled
Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01539343·31 enrolled
Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Completed·SSt. Jude Children's Research Hospital·Phase 3·NCT01472965·95 enrolled
Catheter Related - Gram Positive Bloodstream Infections
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00467272·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)